Welcome to AMYPAD!
We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.
The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:
- improve the diagnostic work-up of people suspected to have Alzheimer’s disease and their management
- understand the natural history of the disease in a pre-symptomatic stage
- select people for treatment trials aiming at preventing Alzheimer’s disease
💡 You can now make a formal request to access our data!
|
|
|
Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
Main enrollment barriers in the AMYPAD PNHS
02 Nov 2023
The AMYPAD PNHS is a unique opportunity to study enrollment barriers in the pre-dementia population...
Development of a framework for harmonizing brain PET scans
31 Oct 2023
Researchers assessed the performance of a framework for the harmonization of brain PET scans...
New paper assessing the assessment of amyloid PET scans
28 Oct 2023
AMYPAD researchers investigated the impact of simulated reduced injected dose on the assessment of amyloid PET scans...
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.
